Abstract
In spite of the high mortality in pancreatic cancer, significant progress is being made. This review discusses multimodality therapy for patients with pancreatic cancer. Surgical therapy currently offers the only potential monomodal cure for pancreatic adenocarcinoma. However only 10%–20% of patients present with tumors that are amenable to resection, and even after resection of localized cancers, long term survival is rare. The addition of chemoradiation therapy significantly increases median survival. To achieve long-term success in treating this disease it is therefore increasingly important to identify effective neoadjuvant/adjuvant multimodality therapies. Preoperative chemoradiation for potentially resectable pancreatic cancer has the following advantages: (1) neoadjuvant treatment would eliminate the delay of adjuvant treatment due to postoperative complications; (2) neoadjuvant treatment could avoid unnecessary surgery for patients with metastatic disease evident on restaging after neoadjuvant therapy; (3) downstaging after neoadjuvant therapy may increase the likelihood for negative surgical margins; and (4) neoadjuvant treatment could prevent peritoneal tumor cell implantation and dissemination caused during surgery. This review systematically summarizes the current status, controversies, and prospects of neoadjuvant treatment of pancreatic cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer, 2001, 37(Suppl 8): S4–S66.
Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin, 2005, 55: 10–30.
Wagner M, Redaelli C, Lietz M, et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg, 2004, 91: 586–594.
Stocken DD, Buchler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer, 2005, 92: 1372–1381.
Beger HG, Rau B, Gansauge F, et al. Treatment of pancreatic cancer: challenge of the facts. World J Surg, 2003, 27: 1075–1084.
Tsai JY, Iannitti DA, Safran H. Combined modality therapy for pancreatic cancer. Semin Oncol, 2003, 30(Suppl 9): 71–79.
Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg, 1999, 230: 776–782.
Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med, 2004, 350: 1200–1210.
Beger HG, Poch B, Schwarz M, et al. Pancreatic cancer: the relative importance of neoadjuvant therapy. Chirurg, 2003, 74: 202–207.
Smeenk HG, Tran TC, Erdmann J, et al. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg, 2005, 390: 94–103.
Pedrazzoli S, DiCarlo V, Dionigi R, et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg, 1998, 228: 508–517.
Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg, 2002, 236: 355–366.
Demeure MJ, Doffek KM, Komorowski RA, et al. Adenocarcinoma of the pancreas: detection of occult metastases in regional lymph nodes by a polymerase chain reaction-based assay. Cancer, 1998, 83: 1328–1334.
Hermanek P. Pathology and biology of pancreatic ductal adenocarcinoma. Langenbecks Arch Surg, 1998, 383: 116–120.
Kayahara M, Nagakawa T, Futagami F, et al. Lymphatic flow and neural plexus invasion associated with carcinoma of the body and tail of the pancreas. Cancer, 1996, 78: 2485–2491.
Juhl H, Kalthoff H, Kruger U, et al. Immunocytologic detection of disseminated tumor cells in the peritoneal cavity and bone marrow in patients with pancreatic carcinoma. Chirurg, 1994, 65: 1111–1115.
Inoue S, Tezel E, Nakao A. Molecular diagnosis of pancreatic cancer. Hepatogastroenterology, 2001, 48: 933–938.
Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001, 345: 725–730.
Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med, 1991, 324: 709–715.
Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer, 1987, 59: 2006–2010.
Kapiteijn E, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med, 2001, 345: 638–646.
Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg, 2003, 237: 74–85.
Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg, 1985, 120: 899–903.
Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol, 1997, 15: 928–937.
Fogelman DR, Chen J, Chabot JA, et al. The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX. Surg Oncol Clin N Am, 2004, 13: 711–735.
Chandler NM, Canete JJ, Stuart KE, et al. Preoperative chemoradiation in resectable pancreatic cancer. J Hepatobilary Pancreat Surg, 2003, 10: 61–66.
Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg, 1992, 127: 1335–1339.
Ishikawa O, Ohigashi H, Imaoka S, et al. Is the long-term survival rate improved by preoperative irradiation prior to Whipple’s procedure for adenocarcinoma of the pancreatic head? Arch Surg, 1994, 129: 1075–1080.
Coia L, Hoffman J, Scher R, et al. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys, 1994, 30: 161–167.
Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg, 1996, 171: 118–124.
Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol, 1998, 16: 317–323.
White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol, 2001, 8: 758–765.
Wanebo HJ, Glicksman AS, Vezeridis MP, et al. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Arch Surg, 2000, 135: 81–87.
Snady H, Bruckner H, Cooperman A, et al. Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer, 2000, 89: 314–327.
Mehta VK, Fisher G, Ford JA, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg, 2001, 5: 27–35.
Wilkowski R, Thoma M, Heinemann V, et al. Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer — feasible and effective. Strahlenther Onkol (German), 2003, 179: 78–86.
Magnin V, Moutardier V, Giovannini MH, et al. Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer. Int J Radiat Oncol Biol Phys, 2003, 55: 1300–1304.
Aristu J, Canon R, Pardo F, et al. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol, 2003, 26: 30–36.
Calvo FA, Matute R, Garcia-Sabrido JL, et al. Neoadjuvant chemoradiation with tegafur in cancer of the pancreas: initial analysis of clinical tolerance and outcome. Am J Clin Oncol, 2004, 27: 343–349.
Joensuu TK, Kiviluoto T, Karkkainen P, et al. Phase I–II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys, 2004, 60: 444–452.
Hoffman JP, Weese JL, Solin LJ, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg, 1995, 169: 71–77.
Pisters PW, Abbruzzese JL, Janjan NA, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol, 1998, 16: 3843–3850.
Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res, 2001, 7: 2246–2253.
Gunderson LL, Haddock MG, Burch P, et al. Future role of radiotherapy as a component of treatment in biliopancreatic cancers. Ann Oncol, 1999, 10(Suppl 4): 291–295.
Willett CG, Czito BG, Bendell JC, et al. Locally advanced pancreatic cancer. J Clin Oncol, 2005, 23: 4538–4544.
Sohn TA, Lillemoe KD, Cameron JL, et al. Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome. Ann Surg, 1999, 229: 393–400.
Crane CH, Beddar AS, Evans DB. The role of intraoperative radiotherapy in pancreatic cancer. Surg Oncol Clin N Am, 2003, 12: 965–977.
Kinsella TJ, Sindelar WF. Intraoperative radiotherapy for pancreatic carcinoma. Experimental and clinical studies. Cancer, 1996, 78: 598–604.
Landry JC, Yang GY, Ting JY, et al. Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosim, 2002, 27: 121–129.
Garcea G, Neal CP, Pattenden CJ, et al. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer, 2005, 41: 2213–2236.
Segara D, Biankin AV, Kench JG, et al. Expression of HOXB2, a retinoic acid signaling target in pancreatic cancer and pancreatic intraepithelial neoplasia. Clin Cancer Res, 2005, 11: 3587–3596.
Awada A, Mano M, Hendlisz A, et al. New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective. Expert Rev Anticancer Ther, 2004, 4: 53–60.
Xiong HQ. Molecular targeting therapy for pancreatic cancer. Cancer Chemother Pharmacol, 2004, 54(Suppl 1): S69–S77.
Willett CG, Clark JW. Update on combined-modality treatment options for pancreatic cancer. Oncology (Williston Park), 2003, 17(12 Suppl 13): 29–36.
Lawrence TS. Radiation sensitizers and targeted therapies. Oncology (Williston Park), 2003, 17(12 Suppl 13): 23–28.
Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol, 2004, 72: 257–266.
Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol, 2002, 29(5 Suppl 14): 31–37.
Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol, 2004, 22: 2610–2616.
Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. ASCO Meeting Abstracts, 2005, 23: 1.
Krempien R, Muenter MW, Huber PE, et al. Randomized phase II — study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer — PARC: study protocol [ISRCTN56652283]. BMC Cancer, 2005, 5: 131.
Krempien R, Munter MW, Huber PE, et al. Phase II — study evaluating trimodal therapy with Cetuximab, intensity modulated radiotherapy (IMRT) and gemcitabine for patients with locally advanced pancreatic cancer [ISRCTN56652283]. ASCO 2006, Abstract 4100.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Krempien, R., Munter, M.W., Harms, W. et al. Pancreatic cancer — Neoadjuvant therapy. Chinese German J Clin Oncol 6, 162–169 (2007). https://doi.org/10.1007/s10330-007-0046-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-007-0046-z